I've posted several in the past especially the large Japanese S1 failed trials.
Anavex did trials on moderate to mild, not severe dementia.
The truth is that even if bryostatin had passed the trials its effect on severe dementia would not have made a significant change in the quality of life of severe dementia patients.
Anavex has 21 people still on the drug after more than five years.
News 
Market Data 
Discover 
